We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Chicago, IL – January 10, 2019 – Zacks Market Edge is a podcast hosted weekly by cks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here:
Pot Stocks in 2019: A Year of Transition
Welcome to Episode #161 of the Zacks Market Edge Podcast.
Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life.
In this episode, Tracey is joined by Zacks Stock Strategist, and the editor of Zacks new upcoming newsletter the Marijuana Innovators, David Borun to discuss the events of 2018 that took the marijuana industry in a new direction and what it will mean for investors getting into the pot stocks in 2019.
2018: The Year of Hope
2018 was filled with great expectations for pot stock investors. Canada was set to legalize the recreational use of marijuana on October 17.
In anticipation, the publicly traded pot stocks like Tilray (TLRY - Free Report) , Aurora Cannabis and others saw big gains.
But October 17 came and went and the “hope trade” turned into the “reality trade” as now companies had to execute in an environment that was still fraught with different regulations and expectations.
The hot pot stocks also saw big declines in the market correction at the end of the year.
Is this a buying opportunity in some of the names?
2019: The Year of Reality
There seem to be more opportunities than ever before in the cannabis industry. The American Farm Bill , which was signed by President Trump into law on Dec 20, 2018, could also have a big impact on the agriculture and consumer product industries.
The bill classified hemp as an agriculture commodity and removed it from the DEA’s list of controlled substances. This will free up farmers to grow hemp, at least in the states where it is currently legal to do so, which must have less than 0.3% of THC.
Hemp can be used in a variety of ways including in clothing, can be put in food and drink, as a supplement and in make-up and beauty products.
But it’s wrong to think that companies will just jump into the hemp market. The FDA has already warned that food and drink products with CBD must get FDA approval.
In 2019, while growth opportunities are there, the stakes are getting much higher. That’s why investors might want to go with some of the established names already in the industry.
3 Stocks Already in the Cannabis Industry
1. Constellation Brands (STZ - Free Report) was one of the first in when it took a big stake in Canada’s Canopy Growth with the purpose of making new beverages.
2. Altria Group (MO - Free Report) , the tobacco giant, just made waves by announcing a 45% stake in Canada’s Cronos Corporation. That’s a $1.8 billion bet on the cannabis industry.
3. GW Pharmaceuticals is a British drug company that is the first to get a cannabis drug approved. It’s cannabis drug, Epidiolex, is used by epilepsy patients.
2019 should also be a big year with new companies jumping into the cannabis fray.
What else should you know about the pot stocks in 2019?
Tune into this week’s podcast to find out.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zacks Market Edge Highlights: Tilray, Constellation Brands, Altria and GW Pharmaceuticals
For Immediate Release
Chicago, IL – January 10, 2019 – Zacks Market Edge is a podcast hosted weekly by cks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here:
Pot Stocks in 2019: A Year of Transition
Welcome to Episode #161 of the Zacks Market Edge Podcast.
Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life.
In this episode, Tracey is joined by Zacks Stock Strategist, and the editor of Zacks new upcoming newsletter the Marijuana Innovators, David Borun to discuss the events of 2018 that took the marijuana industry in a new direction and what it will mean for investors getting into the pot stocks in 2019.
2018: The Year of Hope
2018 was filled with great expectations for pot stock investors. Canada was set to legalize the recreational use of marijuana on October 17.
In anticipation, the publicly traded pot stocks like Tilray (TLRY - Free Report) , Aurora Cannabis and others saw big gains.
But October 17 came and went and the “hope trade” turned into the “reality trade” as now companies had to execute in an environment that was still fraught with different regulations and expectations.
The hot pot stocks also saw big declines in the market correction at the end of the year.
Is this a buying opportunity in some of the names?
2019: The Year of Reality
There seem to be more opportunities than ever before in the cannabis industry. The American Farm Bill , which was signed by President Trump into law on Dec 20, 2018, could also have a big impact on the agriculture and consumer product industries.
The bill classified hemp as an agriculture commodity and removed it from the DEA’s list of controlled substances. This will free up farmers to grow hemp, at least in the states where it is currently legal to do so, which must have less than 0.3% of THC.
Hemp can be used in a variety of ways including in clothing, can be put in food and drink, as a supplement and in make-up and beauty products.
But it’s wrong to think that companies will just jump into the hemp market. The FDA has already warned that food and drink products with CBD must get FDA approval.
In 2019, while growth opportunities are there, the stakes are getting much higher. That’s why investors might want to go with some of the established names already in the industry.
3 Stocks Already in the Cannabis Industry
1. Constellation Brands (STZ - Free Report) was one of the first in when it took a big stake in Canada’s Canopy Growth with the purpose of making new beverages.
2. Altria Group (MO - Free Report) , the tobacco giant, just made waves by announcing a 45% stake in Canada’s Cronos Corporation. That’s a $1.8 billion bet on the cannabis industry.
3. GW Pharmaceuticals is a British drug company that is the first to get a cannabis drug approved. It’s cannabis drug, Epidiolex, is used by epilepsy patients.
2019 should also be a big year with new companies jumping into the cannabis fray.
What else should you know about the pot stocks in 2019?
Tune into this week’s podcast to find out.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/performance
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.